Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 11/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180578 | 0.80 | KDM4E (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14054011 | 0.79 | POLB (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3401473 | 0.78 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22873005 | 0.78 | L3MBTL1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1180651 | 0.77 | POLB (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1180413 | 0.75 | P2RX4 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24227341 | 0.75 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13456337 | 0.73 | CYP1A2 (0.56) | KDM4E | |
| SCHEMBL24227323 | 0.73 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22873260 | 0.73 | ATM (0.46) | MEN1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852572-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Eli Lilly and Company (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2013176698-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | ELI LILLY AND COMPANY (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2247558-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Siemens Medical Solutions USA, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SLC18A3, TSPO, CHAT | PSEN1 25/4885PSEN2 38/4885APH1B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.